Altimmune, Inc. (ALT): debt financing — Altimmune Q3 net loss $19M ($0.21/sh); cash $210.8M; debt facility upsized to $125M

Altimmune, Inc.

2025-Q3 EPS reported -$0.74 vs consensus -$0.28 ▼ miss (-160.3%)

Cash and investments $210.8M, up 60% from Dec 2024; net loss $19.0M vs $22.8M year ago.
Hercules loan amended to $125M; drew additional $20M at close; interest-only period extended to 30 months.
Phase 2b IMPACT 48-week MASH data expected before year end; End-of-Phase-2 FDA meeting scheduled Q4 2025.
RECLAIM AUD trial enrollment completed early; topline results expected in 2026. RESTORE ALD trial initiated.
Appointed CMO (Dr. Arbet-Engels), CCO (Richardson), and CLO (Abrams) to executive team.

item 1.01 item 2.02 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

Altimmune, Inc. amended term loan of from an aggregate principal amount of $100.0 million to $125.0 million with Hercules Capital, Inc. at greater of (a) 9.70% per annum and (b) the prime rate as reported in The Wall St maturing 30 months from May 13, 2025.

Instrument: term loan
Principal: from an aggregate principal amount of $100.0 million to $125.0 million
Counterparty: Hercules Capital, Inc.
Rate: greater of (a) 9.70% per annum and (b) the prime rate as reported in The Wall St
Maturity: 30 months from May 13, 2025
Event: amendment

Exact text from the filing

Company and Hercules. Under the terms of the Amendment, the lenders will, among other things, increase the availability under the Term Loan from an aggregate principal amount of $100.0 million to $125.0 million. The first Term Loan tranche was drawn down at closing on May 13, 2025 in an aggregate principal amount of $15.0 million. The second Term Loan tranche was drawn

View on SEC.gov

317 debt financings filed in the last 30 days. Browse all debt financings →

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-25-000055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.